Celgene Targets Cancer Stem Cells with US$3.3 B OncoMed Collaboration

By Heather Cartwright

Pharma Deals Review: Vol 2013 Issue 12 (Table of Contents)

Published: 19 Dec-2013

DOI: 10.3833/pdr.v2013.i12.1996     ISSN: 1756-7874

Section: Licensing



Continuing its strategy of investing in novel therapeutic approaches in oncology via option-based deals, Celgene has formed a broad collaboration with OncoMed Pharmaceuticals that is potentially worth more than US$3...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details